Back to search

Article

Epigenomic evolution in chronic lymphocytic leukaemia cells from patients treated with ibrutinib and showing disease progression

2020-06-18

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib provided a breakthrough in the treatment of chronic lymphocytic leukaemia (CLL), but cases of resistance are now emerging. Whilst resistance is commonly associated with mutations in BTK itself and the downstream signalling molecule PLCg2, this is not always the case. In a recent study, we have detected some ep...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
01e634da-4113-5c3a-a30e-7b2cc2c824d6
DOI
10.21203/rs.3.rs-33939/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Epigenomic evolution in chronic lymphocytic leukaemia cells from patients treated with ibrutinib and showing disease progressionDOI 10.21203/rs.3.rs-33939/v1
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.Semantic proximity
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapseSemantic proximity
Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLLSemantic proximity
Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLLSemantic proximity
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemiaSemantic proximity
Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinibSemantic proximity
Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib drug response in chronic lymphocytic leukemiaSemantic proximity
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.Semantic proximity
Genomic evolution of ibrutinib‐resistant clones in Waldenström macroglobulinaemiaSemantic proximity
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.Semantic proximity
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.Semantic proximity
Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Semantic proximity
Select a neighboring publication to make it the new centre.